Helus Pharma (NASDAQ:HELP) is approaching a crucial Q4 readout that could reshape the investment story. The company says its earlier depression data showed durable remission after only two doses, but Phase 3 is the real test. If the trial confirms the promise, investors may start looking at Helus very differently.
Interview date: July 1, 2026. The video was published on July 11, 2026. A portion of this video is sponsored by Simply Wall St. Dividend Aristocrats® is a registered trademark of Standard & Poor’s Financial Services LLC. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video. This video is for educational purposes only and not financial advice.
